NovaBay (NBY) | Financial Analysis & Statements
NovaBay Pharmaceuticals, Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
-521.0K
Operating Income
-1.8M
Net Income
-26.6M
Balance Sheet Metrics
Total Assets
9.0M
Total Liabilities
32.2M
Shareholders Equity
-23.2M
Cash Flow Metrics
Operating Cash Flow
-26.6M
Free Cash Flow
-2.3M
Revenue & Profitability Trend
NovaBay Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 9.8M | 14.7M | 14.4M | 10.2M |
| Cost of Goods Sold | - | 3.3M | 6.8M | 6.6M | 3.7M |
| Gross Profit | - | 6.5M | 7.9M | 7.8M | 6.5M |
| Gross Margin % | 0.0% | 66.3% | 53.6% | 54.0% | 63.8% |
| Operating Expenses | |||||
| Research & Development | - | 42.0K | 68.0K | 174.0K | 44.0K |
| Selling, General & Administrative | 7.6M | 11.4M | 12.8M | 15.3M | 15.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 7.6M | 11.5M | 12.9M | 15.5M | 15.4M |
| Operating Income | -7.6M | -5.0M | -5.0M | -7.7M | -8.9M |
| Operating Margin % | 0.0% | -50.9% | -34.0% | -53.3% | -86.8% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 277.0K | 904.0K | - | - | - |
| Other Non-Operating Income | -25.4M | -1.3M | -4.6M | -2.9M | 3.0M |
| Pre-tax Income | -33.2M | -7.2M | -9.6M | -10.6M | -5.8M |
| Income Tax | - | - | - | - | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -22.1M | -7.2M | -9.6M | -10.6M | -5.8M |
| Net Margin % | 0.0% | -73.8% | -65.5% | -73.6% | -57.1% |
| Key Metrics | |||||
| EBITDA | -7.5M | -5.1M | -2.2M | -4.5M | -13.4M |
| EPS (Basic) | $-19.00 | $-12.65 | $-138.60 | $-353.50 | $-184.10 |
| EPS (Diluted) | $-19.00 | $-12.65 | $-138.60 | $-353.50 | $-184.10 |
| Basic Shares Outstanding | 1164000 | 679200 | 120428 | 46000 | 35628 |
| Diluted Shares Outstanding | 1164000 | 679200 | 120428 | 46000 | 35628 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
NovaBay Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 8.0M | 430.0K | 3.1M | 5.4M | 7.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | 389.0K | 759.0K | 2.0M | 1.7M |
| Inventory | - | 765.0K | 2.9M | 3.4M | 3.2M |
| Other Current Assets | 177.0K | 110.0K | 81.0K | 159.0K | 129.0K |
| Total Current Assets | 8.7M | 1.9M | 7.2M | 11.3M | 13.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 0 | 0 | 0 | 1.8M | 114.0K |
| Goodwill | - | - | 0 | 3.0M | 14.3M |
| Intangible Assets | - | - | - | 2.3M | 5.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 360.0K | 480.0K | 497.0K | 489.0K | 476.0K |
| Total Non-Current Assets | 360.0K | 1.5M | 1.9M | 5.1M | 10.8M |
| Total Assets | 9.0M | 3.4M | 9.0M | 16.4M | 24.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 257.0K | 623.0K | 1.1M | 1.1M | 1.0M |
| Short-term Debt | 489.0K | 963.0K | 1.6M | 453.0K | 305.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 1.1M | 2.8M | 4.3M | 4.3M | 3.4M |
| Non-Current Liabilities | |||||
| Long-term Debt | 287.0K | 709.0K | 1.1M | 1.6M | 246.0K |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | 334.0K | - | 561.0K |
| Total Non-Current Liabilities | 31.1M | 709.0K | 1.4M | 1.6M | 10.4M |
| Total Liabilities | 32.2M | 3.6M | 5.7M | 5.8M | 13.8M |
| Equity | |||||
| Common Stock | 252.0K | 49.0K | 112.0K | 20.0K | 478.0K |
| Retained Earnings | -210.4M | -183.5M | -174.8M | -158.2M | -141.9M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -23.2M | -129.0K | 3.3M | 10.6M | 10.2M |
| Key Metrics | |||||
| Total Debt | 776.0K | 1.7M | 2.7M | 2.0M | 551.0K |
| Working Capital | 7.5M | -908.0K | 2.9M | 7.1M | 9.7M |
Balance Sheet Composition
NovaBay Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -33.2M | -7.1M | -9.6M | -10.6M | -5.8M |
| Depreciation & Amortization | 140.0K | 381.0K | 203.0K | 483.0K | 119.0K |
| Stock-Based Compensation | 29.0K | 148.0K | 291.0K | 220.0K | 1.2M |
| Working Capital Changes | -520.0K | -547.0K | 578.0K | 315.0K | 14.0K |
| Operating Cash Flow | -33.3M | -6.0M | -6.9M | -10.2M | -4.5M |
| Investing Activities | |||||
| Capital Expenditures | - | -6.0K | -19.0K | -112.0K | -52.0K |
| Acquisitions | - | 1.1M | - | 0 | -12.0M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | - | 1.1M | -19.0K | -112.0K | -12.0M |
| Financing Activities | |||||
| Share Repurchases | -175.0K | - | - | - | - |
| Dividends Paid | -4.8M | - | - | - | - |
| Debt Issuance | - | - | - | - | 0 |
| Debt Repayment | -2.5M | -2.0M | -1.5M | -105.0K | 0 |
| Financing Cash Flow | -1.7M | -737.0K | -129.0K | 2.8M | 16.8M |
| Free Cash Flow | -8.4M | -5.2M | -4.2M | -6.8M | -9.2M |
| Net Change in Cash | -35.0M | -5.7M | -7.0M | -7.4M | 206.0K |
Cash Flow Trend
NovaBay Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
0.04
Forward P/E
-2.38
PEG Ratio
-2.38
Profitability Ratios
Profit Margin
0.00%
Operating Margin
350.10%
Return on Equity
95.53%
Return on Assets
-76.11%
Financial Health
Current Ratio
7.60
Debt to Equity
-0.03
Beta
0.16
Per Share Data
EPS (TTM)
$-28.50
Book Value per Share
$-0.92
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NBY | 34.3M | 0.04 | - | 95.53% | 0.00% | -0.03 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






